Home World News Lorlatinib Continues to Show Long-Term Benefit in Newly-Diagnosed Patients with Advanced ALK-positive... World News Lorlatinib Continues to Show Long-Term Benefit in Newly-Diagnosed Patients with Advanced ALK-positive NSCLC By Ogkologos - July 14, 2026 207 0 Facebook Twitter Google+ Pinterest WhatsApp Findings after 7 years of follow-up in the CROWN study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Spring Budget 2023: What does it mean for the mission to... March 15, 2023 First-Line Treatment with Ribociclib plus Letrozole Shows a Significant Overall Survival... March 22, 2022 FDA Approves Durvalumab for Locally Advanced or Metastatic Biliary Tract Cancer September 14, 2022 T-DM1 Approval Expanded to Include Some Women with Early-Stage HER2-Positive Breast... May 23, 2019 Load more HOT NEWS How to Improve Cancer-Related Fatigue Using Exercise: Expert Perspectives EMA Recommends Granting a Conditional Marketing Authorisation for Tovorafenib Νέα διαγνωστική μέθοδος για τον καρκίνο, με τη συμβολή της Microsoft Drug Combination May Have Potential for Cancers with TP53 Mutations
